Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort J. Cadranel, B. Coudert, A. Mauguen, S. Friard, E. Quoix, J. Madelaine, V. Westeel, C. Daniel, A. Madroszyk, E. Dansin, A. Scherpereel, E. Fabre-Guillevin, R. Gervais, D. Moro-Sibilot, P. Foucher, F. Morin, C. Chouaid, J. P. Pignon (Paris, Dijon, Villejuif, Suresnes, Strasbourg, Caen, Besançon, Marseille, Lille, Grenoble, France)
Source: Annual Congress 2010 - The role of biomarkers in lung cancer
Session: The role of biomarkers in lung cancer Session type: Oral PresentationNumber: 1942
Disease area: Thoracic oncologyRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Cadranel, B. Coudert, A. Mauguen, S. Friard, E. Quoix, J. Madelaine, V. Westeel, C. Daniel, A. Madroszyk, E. Dansin, A. Scherpereel, E. Fabre-Guillevin, R. Gervais, D. Moro-Sibilot, P. Foucher, F. Morin, C. Chouaid, J. P. Pignon (Paris, Dijon, Villejuif, Suresnes, Strasbourg, Caen, Besançon, Marseille, Lille, Grenoble, France). Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort. Eur Respir J 2010; 36: Suppl. 54, 1942
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
The importance of the disease-free survival (DFS) endpoint to survivors of lung cancer Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021
Different efficacy between carboplatin (Cpl) and gemcitabine (Gem) on median survival time of elderly non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC). Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017
Safety analysis of anti-VEGF therapy bevacizumab (Bv) in patients (pts) with untreated advanced non-small cell lung cancer (NSCLC) in MO19390 (SAiL) trial Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008
Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S) Source: Eur Respir J 2002; 20: Suppl. 38, 597s Year: 2002
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019
A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005
Benefit of immune checkpoint inhibitors (ICIs) for second-line treatment of advanced non-small cell lung cancer (NSCLC) using restricted mean survival time (RMST). Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care. Source: International Congress 2019 – Treatment of lung cancer Year: 2019
Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015
Concurrent chemoradiation in stage III NSCLC: High eligilbility and high rates of overall and progression-free survival with acceptable toxicity Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010
Early concurrent chemoradiotherapy for limited small cell lung cancer (LSCLC). Analysis of toxicity and survival of 30 consecutive patients Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004